review of existing studies on ASL in dementia Marion Smits, MD PhD

Similar documents
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS

FDG-PET e parkinsonismi

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

NIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.

Form D1: Clinician Diagnosis

Neuro degenerative PET image from FDG, amyloid to Tau

Brain imaging for the diagnosis of people with suspected dementia

Dementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Imaging of Alzheimer s Disease: State of the Art

Confronting the Clinical Challenges of Frontotemporal Dementia

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Diffusion Tensor Imaging in Dementia. Howard Rosen UCSF Department of Neurology Memory and Aging Center

Mild Cognitive Impairment (MCI)

Dementia and Healthy Ageing : is the pathology any different?

Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

Regulatory Challenges across Dementia Subtypes European View

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Parkinson e decadimento cognitivo. Stelvio Sestini

Dr Fiona Kumfor University of Sydney

Clinical Genetics & Dementia

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013

212 Index C-SB-13,

Dementia and Alzheimer s disease

Caring Sheet #11: Alzheimer s Disease:

Supplementary Online Content

I do not have any disclosures

Do not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009

Vascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center

Secondary prevention of Alzheimer s dementia: neuroimaging contributions

Frontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.

Diabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian

Synaptic changes in dementia: links to cognition and behaviour

Neuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD

CEREBRUM. Dr. Jamila EL Medany

Clinical, molecular imaging and biomarker concordance in the diagnosis of Alzheimer s disease and vascular dementia

! slow, progressive, permanent loss of neurologic function.

FTD basics! Etienne de Villers-Sidani, MD!

Recommendations for the Diagnosis and Treatment of Dementia 2012

Assessing and Managing the Patient with Cognitive Decline

Update on functional brain imaging in Movement Disorders

New life Collage of nursing Karachi

Supplementary Online Material Supplementary Table S1 to S5 Supplementary Figure S1 to S4

Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.

Delirium & Dementia. Nicholas J. Silvestri, MD

Diagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology

Amsterdam Dementia Cohort: Performing Research to Optimize Care

Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

Visual Dysfunction in Alzheimer s Disease and Parkinson s Disease

Clinical Applications of fmri

Diagnosis and Treatment of Alzhiemer s Disease

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

Prof Tim Anderson. Neurologist University of Otago Christchurch

Dementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Assessing Cognition. Andreana Haley, Ph.D. Department of Psychology University of Texas at Austin

Outline. Facts and figures Action plans Early / correct diagnosis Conclusions

correlates with social context behavioral adaptation.

The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer

Imaging biomarkers for Parkinson s disease

Is PET/CT really helpful in diagnosing Alzheimer s Disease?

How can the new diagnostic criteria improve patient selection for DM therapy trials

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

brain MRI for neuropsychiatrists: what do you need to know

Neuroimaging in Dementia

Non Alzheimer Dementias

Differential diagnosis of Frontotemporal Dementia FTLD using visual rating scales

UNIVERSITY OF WESTERN ONTARIO

Differential Diagnosis

Visual Rating Scale Reference Material. Lorna Harper Dementia Research Centre University College London

Dementia. Dr Maria Foundas Consultant Physician. Training support Skills development Competency Assessment Scholarships Education

MRI of Pathological Aging Brain

Diagnosis of Alzheimer s Disease with [18F]PET in Mild and Asymptomatic Stages

Assessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia

An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease

DEMENTIA 9/29/16. Introduction. Introduction. Signs and Symptom. Epidemiology. Dementia. Dr. Yotin Chinvarun M.D. Ph.D.

CEREBRUM Dr. Jamila Elmedany Dr. Essam Eldin Salama

SUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)

Neuro-Imaging in dementia: using MRI in routine work-up Prof. Philip Scheltens

Part 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University

The ABCs of Dementia Diagnosis

Nuclear neurology. Zámbó Katalin Department of Nuclear Medicine

3.3. Cerebral perfusion in the predementia stages of Alzheimer s disease

Cerebral correlates of psychotic syndromes in neurodegenerative diseases

PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

Provider Led Entity. CDI Quality Institute PLE Neurocognitive Disorders AUC 02/05/2019

LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION

Transcription:

review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam (NL) source: depositphotos.com 1&

frontotemporal&demen2a& HIV&demen2a& Cor2cobasal&degenera2on& Parkinson s&demen2a& Lewy&Body&demen2a& Alzheimer s+disease+ Seman2c&demen2a& mul2system&atrophy& Primary&progressive&aphasia& Creutzfeld;Jakob&disease& Pick s&disease& Vascular&demen2a& Progressive&supranuclear&palsy& Alzheimer s Association 2013: www.alz.org 2&

Alzheimer s,disease,is,not,, just,memory,loss,,alzheimer s,kills, Alzheimer s Association 2013: www.alz.org Biomarker development! Therapeutic interventions most effective in early stages! maybe even in the preclinical stage early disease detection required.! Need for quantitative outcome measures in clinical trials disease monitoring required. 3&

Molecular biomarkers PiB-PET (amyloid deposition). CSF Aβ 1-42 (amyloid deposition). CSF tau protein (neuronal degeneration).! high sensitivity to early disease and histological measures of pathology.! limited sensitivity to clinical status and capacity to track disease progression. Functional biomarkers! Reflect synaptic activity more sensitive to disease activity.! Quantification allows for longitudinal measurements of drug effects. FDG-PET (glucose metabolism). ASL-MRI (cerebral blood flow). 4&

Alzheimer frontotemporal vascular THE DEMENTIAS 5&

Alzheimer s disease Clinical presentation! progressive memory impairment.! loss of episodic memory.! disorientation in time and place.! disturbance of executive and visuospatial function, praxis.! later: focal neurological deficits aphasia. Pathology! atrophy enlargement of ventricles and sulci.! entorhinal cortex limbic system higher order cortex.! neurofibrillary tangles and neuritic plaques. 6&

hippocampal atrophy temporal atrophy parietal atrophy global atrophy ASL in Alzheimer s disease! Regional hypoperfusion (~ regional hypometabolism)! posterior cingulate cortex (PCC)! precuneus! inferior parietal lobe! lateral prefrontal cortex.! Global hypoperfusion Asslani et al. J Cereb Blood Flow Metab 2008;28:725. 7&

ASL for early diagnosis of dementia * p<0.01 ** p<0.001 Regions involved in dementia Regions spared in dementia Steketee et al. submitted Hypoperfusion and atrophy! Hypoperfusion commonly exceeds atrophy precedes tissue loss.! Discordant regions! hippocampus! anterior cingulate cortex. Alsop et al. Neuroimage 2008;42:1267 8&

hypoperfusion atrophy Alsop et al. Neuroimage 2008;42:1267 hypoperfusion atrophy Alsop et al. Neuroimage 2008;42:1267 9&

The hippocampus Hyper perfusion! decoupling with vascular compromise! local inflammation! plastic remodelling! compensatory response! methodology? Hypo perfusion! before PVE correction Binnewijzend et al. Radiology 2013;267:221 Often not imaged. Alsop et al. Neuroimage 2008;42:1267 Comparison of ASL with FDG-PET! 15 AD vs 19 controls.! High concordance with simultaneous ASL and FDG-PET.! Comparable diagnostic accuracy (AUC)! ASL 0.94 (0.77-0.99)! PET 0.92 (0.76-0.99). Chen et al. Neurology 2011;77:1977 10&

ASL in prodromal AD: MCI! Important target population for disease modifying therapeutics.! Regional hypoperfusion (consistent with FDG-PET & AD)! PCC! precuneus! parietal regions! to lesser extent than in AD.! Also hyperperfusion Dai et al. Radiology 2009;250:856! hippocampus! amygdala! striatum. Correlation with disease severity! Studies are scarce.! Generally correlated with MMSE (crude!).! Regional hypoperfusion! (lateral) parietal and parieto-occipital cortices! early stage AD or MCI: PCC. 11&

AD converters precuneus middle cingulum inferior parietal lobe middle frontal cortex Predictors of decline precuneus (selective attention, activities of daily living, dementia score) inferior parietal lobe (dementia score) middle cingulum (dementia score) Chao et al. Alzheimer Dis Assoc Disord 2010;24:19 large patient population 71 AD patients 31 MCI patients 70 subjective complaints (SC) correlation with MMSE parietal cortex precuneus PCC Binnewijzend et al. Radiology 2013;267:221 12&

Task-related ASL MRI in early AD! MCI versus controls Xu et al. Neurology 2007;69:1650! resting CBF in precuneus! extent of hypoperfusion in precuneus PCC during memory encoding task! CBF in MTL with task compared with rest in controls CBF.! APOE-ε4 carriers Fleisher et al. Neurobiol Aging 2009;30:1737! resting CBF in the MTL! blunted increase during face-name memory encoding task. Task-related ASL accentuates group differences. Frontotemporal dementia Incidence! 5-10% of cases of dementia! family history (1 st degree) positive in 40% Clinical presentation! psychiatric symptoms: depression, behavioural and personality changes! memory deficits! later: language impairment (progressive mutism) Subtypes! behavioural variant FTD: bvftd! semantic dementia: SD! progressive nonfluent aphasia: PNFA 13&

temporal and frontal atrophy asymmetrical left sided temporal lobe atropy Semantic dementia 14&

ASL in FTD! Studies are scarce.! Regional hypoperfusion! prefrontal cortex! insula.! No studies on specific subtypes. Semantic dementia marked hypoperfusion bilateral insula left >> right hyperfusion temporal lobe 15&

Hu et al. Neurology 2010;75:881 FTD<controls FTD>AD regional hypoperfusion regional hyperperfusion Du et al. Neurology 2006;67:1215 16&

FTD versus controls concordance atrophy with CBF - R prefrontal cortex - medial frontal lobe discordance atrophy without CBF - premotor cortex Shimizu et al. Brain Im&Beh 2010;4:46 Vascular dementia Incidence! most common cause of dementia after Alzheimer disease! association with vascular risk factors Clinical presentation! more sudden onset than Alzheimer disease! stepwise pattern with sudden onsets of deterioration! more commonly small vessel disease with gradual deterioration 17&

multiple lacunar infarcts carotid occlusion frontal and parietal infarcts in the dominant hemisphere ASL in vascular dementia (VaD)! Largely un(der)explored.! No coherent regional metabolic/perfusion pattern described! preferential changes in frontal lobes have been reported! generally no PVE correction in PET/SPECT studies! disruption of (frontal) cortical-subcortical connections.! ASL may show tissue at risk for future infarcts! resting CBF! reactivity measurements of cerebrovascular reserve.! ASL may establish diagnosis: perfusion (rest/challenge). 18&

Alzheimer s disease vascular dementia Hendrikse et al. NeuroImaging Clin N Am 2012;22:259 ASL in vascular dementia CBF irrespective of atrophy in both AD (n=14) and VaD (n=8) in frontal > parietal lobes in VaD > AD Inverse correlation of CBF with white matter lesion load in frontal > parietal lobes in VaD > AD ( ) VaD ( ) AD ( ) controls Schuff et al. Alzheimers Dement 2009;5:454 19&

high incidence of dementia post-stroke (15-30%) patient population 39 patients (>75y) 6 years post-stroke - 8 with dementia 17 AD patients 29 healthy controls large vessel vascular dementia Firbank et al. Neurology 2011;76:1478 control AD AD: parietal & prefrontal cortex post-stroke no dementia post-stroke: global CBF reduction post-stroke dementia CBF AD > poststroke dementia: global & precentral gyrus Firbank et al. Neurology 2011;76:1478 20&

Presenile dementia Patient 63y language & memory deficit Ddx: AD / FTD? Presenile dementia Behandeling! Disease onset < 65 years.! Alzheimer s disease most common cause! often with atypical presentation: language, vision, praxis! memory deficits not/less present! no/minor hippocampal atrophy.! Frontotemporal dementia second most common! important differential diagnosis! may be indistinguishable from early AD. 21&

Presenile dementia Cholinesterase inhibitors (Reminyl, Exelon )! may positively influence AD disease course! most effective in the early stage of the disease! may negatively influence FTD! may have serious side effects 25-30% discontinue treatment. Prognosis Prognosis is worse in FTD compared with AD! poorer life expectancy (4.2 versus 6.0 years)! faster loss of activities of daily living! faster decline on MMSE (-6.7 versus -2.3) Rascovsky et al. Neurology 2005;65:397 22&

ASL for early diagnosis of presenile dementia Patient 63y Control 63y Steketee et al. submitted from group studies to THE PATIENT 23&

From group to patient! 13 AD patients, 19 healthy controls! Overall accuracy 70%! Inter-rater reliability κ = 0.7! exceeds structural imaging rating. Raji et al. AJNR 2010;31:847 From group to patient: presenile dementia Threshold CBF values! Thalamus! 42.2 ml/100cc GM/min! sensitivity = 78%! specificity = 65%.! PCC! 52.0 ml/100cc GM/min! sensitivity = 72%! specificity = 70%. Steketee et al. submitted 24&

From group to patient Clinical reading of FDG-PET versus ASL-MRI! 2 readers (expert nuclear medicine physicians)! moderate to moderate-strong intermodality agreement (κ = 0.45-0.61)! sensitivity and specificity comparable between modalities! difference in interobserver agreement! FDG-PET κ = 0.74! ASL-MRI κ = 0.48. Musiek et al. Alzheimers Dement 2012;8:51 From group to patient Clinical reading of FDG-PET versus ASL-MRI.! 9 young (mean 59y) patients! FDG-PET rated by 2 nuclear medicine physicians! ASL-MRI rated by 2 neuroradiologists.! High intra- and intermodality agreement (κ=0.85-0.86)! Diagnostic accuracy (p>0.05)! FDG-PET: 78%! ASL-MRI: 67%. Weyts et al. ESMRMB 2013 25&

Clinical&informa2on& 46&y.o.&female& progressive&neurocogni2ve&deteriora2on& MRI&&&FDG;PET:&?&Alzheimer s&disease& FDG&PET&(27;05;2011)& C/Alzheimer s+disease+ &L&temporal&lobe& &posterior&cingulate& 26&

ASL&MRI&(24;05;2011)& C/Normal+ Normal&L&temporal&lobe& Normal&posterior&cingulate& Diagnosis& Paraneoplas2c&limbic&encephali2s& an2;nmda;receptor&encephali2s& Structural&MRI& ~50%&normal& mild&t2;hyperintensi2es&(medial)&temporal&lobes& leptomeningeal&enhancement.& Perfusion& focal&hyperperfusion&(?&related&to&seizures).& FDG&PET& focal&hyper;&and&hypometabolism&& temporal&lobes,&posterior&cingulate.& 27&

Conclusions! Published studies mainly on AD! generally small sample size! longitudinal studies lacking! generally established disease stage.! Early stage AD MCI! regional hypoperfusion in PCC and precuneus! accentuated with task-based ASL.! Generally concordance with FDG-PET (glucose metabolism) findings! limited direct comparision of diagnostic accuracy.! Conflicting findings in the hippocampus/mtl.! Gap group individual patient level still needs to be bridged. E+marion.smits@erasmusmc.nl+ T+@MarionSmits+ Curr&Opin&Neurol&2012;25:421& + + Acknowledgments& UCL,+London,+UK+ Prof.&Dr.&X.&Golay& M.&Grade+ + + + + GE+Healthcare& & Dr.&G.C.&Houston& & Porto+University,+PT& & Dr.&A.&Bastos&Leite& & & & AMC,+Amsterdam,+NL& Dr.&A.J.&Nederveen& H.J.&Mutsaerts& Erasmus+MC,+RoEerdam,+NL& R.M.E.&Steketee& E.E.&Bron& 28&